Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?

S. Schneeberger, L. Landin, C. Kaufmann, V. S. Gorantla, G. Brandacher, P. Cavadas, W. P A Lee, Warren C Breidenbach, R. Margreiter

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.

Original languageEnglish (US)
Pages (from-to)499-502
Number of pages4
JournalTransplantation Proceedings
Volume41
Issue number2
DOIs
StatePublished - Mar 2009
Externally publishedYes

Fingerprint

Immunosuppression
Hand Transplantation
Transplantation
Maintenance
Organ Transplantation
Monoclonal Antibodies
alemtuzumab

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Schneeberger, S., Landin, L., Kaufmann, C., Gorantla, V. S., Brandacher, G., Cavadas, P., ... Margreiter, R. (2009). Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation? Transplantation Proceedings, 41(2), 499-502. https://doi.org/10.1016/j.transproceed.2009.01.018

Alemtuzumab : Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation? / Schneeberger, S.; Landin, L.; Kaufmann, C.; Gorantla, V. S.; Brandacher, G.; Cavadas, P.; Lee, W. P A; Breidenbach, Warren C; Margreiter, R.

In: Transplantation Proceedings, Vol. 41, No. 2, 03.2009, p. 499-502.

Research output: Contribution to journalArticle

Schneeberger, S, Landin, L, Kaufmann, C, Gorantla, VS, Brandacher, G, Cavadas, P, Lee, WPA, Breidenbach, WC & Margreiter, R 2009, 'Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?', Transplantation Proceedings, vol. 41, no. 2, pp. 499-502. https://doi.org/10.1016/j.transproceed.2009.01.018
Schneeberger, S. ; Landin, L. ; Kaufmann, C. ; Gorantla, V. S. ; Brandacher, G. ; Cavadas, P. ; Lee, W. P A ; Breidenbach, Warren C ; Margreiter, R. / Alemtuzumab : Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?. In: Transplantation Proceedings. 2009 ; Vol. 41, No. 2. pp. 499-502.
@article{d6beb3cf449c400f8214a4c92d327fb6,
title = "Alemtuzumab: Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?",
abstract = "Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.",
author = "S. Schneeberger and L. Landin and C. Kaufmann and Gorantla, {V. S.} and G. Brandacher and P. Cavadas and Lee, {W. P A} and Breidenbach, {Warren C} and R. Margreiter",
year = "2009",
month = "3",
doi = "10.1016/j.transproceed.2009.01.018",
language = "English (US)",
volume = "41",
pages = "499--502",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Alemtuzumab

T2 - Key for Minimization of Maintenance Immunosuppression in Reconstructive Transplantation?

AU - Schneeberger, S.

AU - Landin, L.

AU - Kaufmann, C.

AU - Gorantla, V. S.

AU - Brandacher, G.

AU - Cavadas, P.

AU - Lee, W. P A

AU - Breidenbach, Warren C

AU - Margreiter, R.

PY - 2009/3

Y1 - 2009/3

N2 - Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.

AB - Minimization of immunosuppression has become the key effort in solid organ transplantation. Alemtuzumab, the humanized CD-52 monoclonal antibody, is an effective depleting agent increasingly used in transplantation trials. In this article, we summarize the current experience with alemtuzumab use in hand transplantation and discuss its role in current and future approaches toward minimization of maintenance immunosuppression in reconstructive transplantation.

UR - http://www.scopus.com/inward/record.url?scp=62849099728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=62849099728&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2009.01.018

DO - 10.1016/j.transproceed.2009.01.018

M3 - Article

C2 - 19328912

AN - SCOPUS:62849099728

VL - 41

SP - 499

EP - 502

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 2

ER -